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To evaluate the labeling preferences of medication users and characterize their perceptions
of the comprehensibility and readability of medication labels.
Methods
We conducted a population-based cross-sectional study of medication users aged 18 years
or older in 10 Brazilian capital cities. Perceptions of the comprehensibility and readability of
medication labels in relation to sociodemographic characteristics were evaluated by Pois-
son regression models with robust variance. Labeling preferences were assessed through
questions addressing possible improvements and through the use of digitally simulated
packages.
Results
Of 6,255 medication users interviewed, more than half found it difficult or very difficult to
read (50.8%) and/or understand (52.0%) medication labels. Difficulties were more pro-
nounced for participants aged 40 years or older, with lower levels of education, and non-
whites. Increasing the font size (93.7%), describing the indications for use (95.9%) and con-
traindications (95.6%) on the label, and highlighting the expiration date (96.3%) were the
most widely accepted improvements. In the evaluation of simulated packages, users pre-
ferred factors that improved readability, such as increased font size, use of graphic elements
and color to highlight the concentration of the active ingredient, and contrast between the
font color and background. The new simulated package design, with increased font size,
color to highlight the concentration and contrast between the font color and background,
was preferred over the standard design by 77.0% of participants.
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Conclusion
Based on users’ perceptions, increased font size and use of graphic elements and color to
emphasize critical information, such as expiration date and concentration, are factors that
contribute to making medication labels clearer to users. Pharmaceutical industries and pol-
icy makers should consider these items when developing labels and defining policies on this
issue.
Introduction
In 1999, the Institute of Medicine published the “To Err is Human” report, estimating 100 000
deaths per year caused by errors in hospital care in the United States [1]. More recent studies
estimate that between 210 000 and 440 000 patients each year, in American hospitals, suffer
some type of preventable harm that contributes to their death [2]. Medication errors are a
major component of errors occurring in care settings. These errors are not limited to the hos-
pital setting, being also considered an important public health problem that mainly affects the
vulnerable patient population [3, 4]. Globally, the cost associated with medication errors has
been estimated at US$ 42 billion annually [5].
Factors related to medication labeling account for approximately 33% of all medication
errors [1]. The label is often the first point of interaction between the user and the medication.
Therefore, label information must be legible and understandable to users so that the expected
treatment outcomes can be achieved and medication errors can be prevented [6]. Factors such
as small font size and style, inadequate spacing between words, and font color without con-
trasting background may affect both the readability and comprehensibility of medication
labels by users, impairing the proper identification of the key information necessary to ensure
the safe use of medications. Another factor that hinders the proper identification of medica-
tions is look-alike labeling, particularly in generic drugs, where there appears to be a tendency
to standardize the layout of drug packages and labels across all product lines from the same
manufacturer [6]. Different medications in look-alike packages may increase the risk of confu-
sion between two or more medications by users [6–8]. In this respect, incorporating users’ per-
ception into the package and label design process is essential for the development of readable
and understandable products that can ultimately prevent potential medication errors associ-
ated with this factor [9–11].
The consequences of medication labeling problems are a concern of different regulatory
agencies worldwide. Additionally, users are important stakeholders in the design of medica-
tion labels and should be engaged in the process and have their perceptions considered in pol-
icy making on this topic.
The objective of the present study was to evaluate the labeling preferences of medication
users and characterize their perceptions of the comprehensibility and readability of medication
labels.
Methods
We conducted a cross-sectional study, through a household survey, in 10 Brazilian capital cit-
ies (2 capital cities in each of the 5 macro regions of Brazil): Belém, Boa Vista, Cuiabá, Curitiba,
Fortaleza, Goiânia, Porto Alegre, Recife, Rio de Janeiro, and São Paulo. Brazil is divided into 5
macro regions (South, Southeast, Midwest, North, and Northeast), consisting of a total of 26
States of the Federation and one Federal District.
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This study was commissioned by The Brazilian Health Regulatory Agency (ANVISA) and
conducted by Hospital Moinhos de Vento (HMV), a tertiary center of excellence and member
facility of a federal government program (PROADI-SUS) that funds the development of
research, education, and management activities with potential to contribute to the develop-
ment of the National Unified Health System (SUS). ANVISA technicians, HMV investigators,
and Universidade Federal do Rio Grande do Sul (UFRGS) faculty were involved in the concep-
tion and planning of all stages of the study.
The field research team comprised a centralized coordination and an operational support
crew, and a team of interviewers. The coordination function was in charge of supervising all
data collection processes and stages, including daily quality control of the collected data, while
the operational support crew carried out field supervision and provided logistical support to
the interviewers. A total of 40 interviewers were trained over the course of a face-to-face ses-
sion lasting 2 days. The second day of the session was dedicated to pilot testing of the study
protocol.
In all 10 capital cities, an equal number of census tracts was randomly selected, according
to the 2010 National Census of the Brazilian Institute of Geography and Statistics (IBGE), to
obtain a total of 100 census tracts in the whole sample. In each census tract, households were
systematically surveyed, respecting an interval of 3 houses, in order to obtain a minimum of 60
residents interviewed. The target population for the survey was adults aged 18 years or older
who could read and write and had used at least one medication during the previous year. Indi-
viduals who had vision problems but were not wearing glasses or contact lenses at the time of
the interview were excluded.
Data were collected, in face-to-face interviews, using electronic devices. Interviews were
carried out simultaneously in all 10 selected capital cities; in each city, four interviewers cov-
ered the 10 randomly selected census tracts. The data collection instrument consisted of ques-
tions addressing the following topics: sociodemographic and economic data; information on
medication use; overall perception of difficulty in reading and understanding medication
labels currently available in Brazil; overall satisfaction with medication labels; and labeling
preferences. For the purposes of this study, label was defined as ‘all information printed on
medication packages’.
The following sociodemographic and economic variables were collected: age group (18 to
24 years; 25 to 39; 40 to 59; 60 years or more); schooling (elementary school; high school; col-
lege); personal income (no income; up to 1 minimum wage; 1 to 5 times the minimum wage; 5
or more times the minimum wage; did not answer); and self-reported race/ethnicity (white,
black, mixed, Asian, indigenous, or did not answer). The variable ‘source of medication sup-
ply’ was collected through the question ‘where do you usually obtain your medications?’;
responses were coded into the following categories as appropriate: ‘government’ (SUS facilities
or Brazilian Popular Pharmacy Program) or ‘commercial’ (retail pharmacies and drugstores).
Overall satisfaction with medication labels available in Brazil was rated on a scale from 0 to
10. Overall perception of difficulty in reading medication labels (readability) was assessed
using a 3-point Likert scale for the question ‘Most of the times, how difficult is it for you to
read information written on packages?’ Also, overall perception of difficulty in understanding
medication labels (comprehensibility) was assessed using a 3-point Likert scale for the ques-
tion ‘How difficult is it for you to understand information written on packages?’. The 3 points
of the Likert scale for both questions were ‘very difficult’, ‘difficult’, and ‘not difficult’.
In order to explore and better understand the factors associated with difficulty in reading
and understanding medication labels, two Poisson regression models with robust variance
were constructed. Dependent variables in each model were ‘difficulty in reading labels’ (read-
ability) and ‘difficulty in understanding labels’ (comprehensibility). These two dichotomous
Medication users’ labeling preferences
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variables were derived from the answers to the questions described earlier. ‘Very difficult’ and
‘difficult’ answers were categorized as ‘yes’ and ‘not difficult’ answers were categorized as ‘no’
for the variables ‘difficulty in reading labels’ and ‘difficulty in understanding labels’. The fol-
lowing independent variables were tested in each model: gender; age group; schooling; self-
reported race/ethnicity; current health problems; and occasional or continued use of medica-
tions. The variable ‘current health problems’ was collected through the question ‘Do you have
any health condition?’ (yes; no) to provide a measure of respondents’ general state of health.
The variable ‘occasional or continued use of medications’ was collected through the question
‘Are you currently taking any medicine?’ (yes; no) and was administered to the whole sample.
Labeling preferences were assessed through questions addressing possible improvements
and through the use of digitally simulated packages. The following improvements were pro-
posed to participants: decreased manufacturer name or logo size; less colorful package; addition
of color or drawings to package to differentiate between medications; use of color to highlight
dose; increased font size; medication contraindications printed on package; indications for use
printed on package; and expiration date printed in increased font size and black type.
The simulated packages were designed based on internationally accepted guidelines and
current Brazilian legislation on medication labeling [6, 12–17]. In order to assess participants’
preferences, each simulated package containing a proposed improvement was compared with
a simulated version of an original package currently marketed in Brazil in relation to one of
the following aspects: minimum font size; highlighting of different doses of the same medica-
tion; vertical or horizontal orientation of text on the label; background color; expiration date
and batch number print; use of color to differentiate between drug classes; and use of non-
reflective material for blister packs and printing of information on each blister pocket. The lay-
out of the package used as a basis for comparison was identical to that of the medication sold
by the leading generic drug manufacturer in Brazil (Fig 1). Two final simulated packages were
designed taking into account the aspects proposed individually in the previous simulations.
These 2 proposed designs summarize the recommendations for designing safe labels for
patients provided in guidelines from the European Union, United Kingdom, Canada, and
Australia [6, 12–16].
In order to make the interview more dynamic and to prevent the same respondent from
evaluating all simulated packages (total 13), we developed 4 different questionnaires. Each
questionnaire consisted of 2 different simulations addressing the individual aspects of interest
(containing two or three different simulated packages, Fig 2) and 2 final simulations with the
proposed improvements applied to the packages (Fig 3). The 2 final simulations were evaluated
by the total sample of respondents, while each individual aspect of interest was evaluated by ¼
of the sample. Four interviewers worked in each of the selected cities; each interviewer was
randomly assigned one of the 4 different questionnaires to be administered to respondents in
their assigned census tracts.
The data collected from the interviews were analyzed using IBM SPSS Statistics for Win-
dows, version 18.0, and expressed as absolute and relative frequencies. Pearson’s chi-square
test was used to assess differences between the categories of sociodemographic variables in
relation to difficulty in reading and understanding information provided on the medication
label. The significance level was set at 5% for all analyses. In the Poisson regression models, the
first step in constructing the model was to analyze the variables individually. Those variables
that showed statistical significance, defined as p< 0.2, were included in the multivariable
model (age group, schooling, self-reported race/ethnicity, current health problems, occasional
or continued use of medications). Variables with a statistical significance greater than 0.05 in
this step were removed one by one from the model until only those with statistical significance
less than 0.05, as determined by the Wald test, remained.
Medication users’ labeling preferences
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The study was approved by the Research Ethics Committee of Hospital Moinhos de Vento,
approval number 1.885.498. Written informed consent was obtained from all participants.
Results
A total of 6,255 medication users were interviewed in the 10 capital cities sampled from August
to September 2017. The sociodemographic characteristics of participants and their informa-
tion on medication use are shown in Table 1. More than half of the participants were women
(54%), 43.9% had completed only elementary school and 43.3% were using at least one medi-
cation at the time of the interview.
More than half of the participants found it difficult or very difficult to read (50.8%) and
understand (52.0%) medication labels. Nearly two-thirds (63.7%) rated their overall satisfac-
tion with medication labels as 7 or less (on a scale from 0 to 10).
Table 2 shows prevalence rates and crude and adjusted prevalence ratios (PR) for the out-
comes ‘difficulty in reading labels’ and ‘difficulty in understanding labels’ according to socio-
demographic characteristics, current health problems, and occasional or continued use of
medications. Statistically significant differences (p< 0.001) were found in users’ perceptions
of their difficulty in reading and understanding labels in relation to age, schooling, and race.
Difficulties were particularly pronounced for participants aged 40 years or older, with lower
levels of education, and non-whites.
Users’ acceptance of possible label improvements is shown in Fig 4. Of all improvements
proposed to users, increasing the font size (93.7%), describing the indications (95.9%) and
Fig 1. Simulated version of an original package currently marketed in Brazil.
https://doi.org/10.1371/journal.pone.0212173.g001
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contraindications (95.6%) on the label, and highlighting the expiration date (96.3%) were the
most widely accepted improvements.
Table 3 shows users’ labeling preferences obtained through the evaluation of simulated pack-
ages (Fig 2). Of particular note is the almost unanimous preference of users for printing of expi-
ration date with contrast between the font color and background over embossing or debossing
of text onto the package (98.6%) and for using blister packs with a white background over
uncoated aluminum foil (98.1%). The preference rate for the final proposed design (Fig 3A) was
77.0% compared with the simulated package with a layout identical to that of the medication
sold by the leading generic drug manufacturer in Brazil. Interestingly, participants preferred the
use of vertical text on the package when this aspect was evaluated individually, although in the
most widely accepted final prototype, among other aspects, the text was printed horizontally.
Discussion
More than half of the interviewed Brazilian medication users found it difficult to read and
understand medication labels available in Brazil. This finding is a warning sign, since the diffi-
culties encountered by users may lead to incorrect and unsafe use of medications, jeopardizing
patient safety and imposing an economic burden on the health system [18–20].
Safe medication identification, selection and administration depend not only on the user’s
ability to read and understand information on labels but also on features inherent in labeling,
such as typographic style and design aspects [21, 22]. In our study, 63.7% of participants
reported low satisfaction with medication labels.
For the interviewed users, increased font size (93.7%) and use of contrasting background to
highlight the expiration date (96.3%) and dose (88.0%) are measures that may contribute to
improving labels. Studies have shown that small font size, look-alike labeling and absence of
contrast between the font color and background for information on dose and expiration date
Fig 2. Simulated primary and secondary medication packages presented to participants.
https://doi.org/10.1371/journal.pone.0212173.g002
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are factors that impair the readability of labels [6, 10, 23, 24]. Readability issues due to small
font size, for example, can make it difficult to read important information required to correctly
use the medication, such as concentration, route of administration, and storage conditions.
Look-alike labeling, in turn, a common issue mainly in generic drugs, can contribute to medi-
cation mix-ups, which appear in our study as one of the probable reasons for users’ dissatisfac-
tion, since the suggestion to add color or drawings to differentiate between look-alike labels
was accepted by 82.4% of participants.
Another strategy used in our study to assess users’ opinions about possible label improve-
ments was the analysis of simulated packages. The simulation results confirm the importance
Fig 3. Simulated final proposed designs. A) Standard packaging × proposed prototype. B) Prototype with doses highlighted.
https://doi.org/10.1371/journal.pone.0212173.g003
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Table 1. Sociodemographic characteristics and information on medication use of the participants in the medica-






18 to 24 years 1082 17.3
25 to 39 years 2190 35.0
40 to 59 years 2039 32.6
60 years or more 944 15.1
Schooling
Elementary school 2748 43.9
High school 2115 33.8
College 1392 22.3
Personal incomea
No income 1423 22.7
Up to 1 minimum wage 2022 32.3
1 to 5 minimum wages 2304 36.8
5 or more minimum wages 258 4.1











Occasional or continued use of medications
Yes 2706 43.3
No 3549 56.7
Source of medication supplyb
Government 3357 42.5
Commercial 4548 57.5
Difficulty in reading medication labels
Very difficult 696 11.2
Difficult 2473 39.6
Not difficult 3073 49.2
Difficulty in understanding medication labels
Very difficult 702 11.3
Difficult 2543 40.8
Not difficult 2994 48.0
a In 2017, a minimum wage in Brazil was equivalent to US$ 291.39.
b Multiple response (n = 7,905).
https://doi.org/10.1371/journal.pone.0212173.t001
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of factors such as increased font size, emphasis on the concentration of the active ingredient,
and use of contrasting background to highlight the expiration date. When participants were
presented with a type style in four point sizes and asked to choose the smallest font size with
which they felt most comfortable to read information provided on the label, the largest font size
Table 2. Overall perception of medication users of difficulty in reading and understanding medication labels. (n = 6,255).
















Gender 0.280 0.649 0.334 0.312







Age Group <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
18 to 24 years 40.1 1 1 43.4 1 1




































Schooling <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
College 41.3 1 1 43.0 1 1
























Race <0.001 <0.001 <0.001 <0.001 <0.001 <0.001













Current health problems <0.001 <0.001 <0.001 <0.001









<0.001 <0.001 <0.001 <0.001







a p-values were calculated using Pearson’s chi-square test.
b p-values were calculated using Poisson regression models with robust variance.
c Black, Mixed, Asian and Indigenous
PRc, Crude prevalence ratio; PRa, Adjusted prevalence ratio
https://doi.org/10.1371/journal.pone.0212173.t002
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(Arial 16 point) was preferred twice as much as the other three options (Arial 7.5, 11, and 14
point). In the study conducted by Smither and Braun, the 14-point prints were considered eas-
ier to read than the 9- and 12-point prints [25]. Wogalter and Vigilante evaluated consumers’
preference and understanding of labels with three different font sizes: 4, 7, and 10 point [23].
They concluded that larger font size is preferred and better understood by older adults, while,
for younger adults, font size has no influence on preference and understanding of labels. Cur-
rent Brazilian legislation does not establish the minimum font size to be used on labels. In inter-
national guidelines, however, the minimum recommended font size is 12 point [6, 13, 17].
The use of graphic elements or color to highlight the concentration of the active ingredient
helped distinguish between different concentrations of the same medication for 83.2% of par-
ticipants. Studies have shown that the use of color (as opposed to monochrome) for key infor-
mation, such as medication name and concentration, helps users identify information faster
and more accurately [24, 26, 27]. Guidelines for the design of medication labels recommend
the use of graphic elements, such as different type styles, boldface, colors, and shapes, to high-
light concentrations mainly on look-alike packages from the same manufacturer [6, 13, 17]. In
Brazil, current legislation on medication labeling does not address the use of graphic elements
or color to highlight the concentration of the active ingredient [16].
Batch number and expiration date are essential information for product traceability and
safe medication use. Although national legislation prohibits the embossing or debossing of
batch number and expiration date onto a package when this method does not provide suffi-
cient contrast on its own, this is a common practice in Brazil [16]. The identification of this
information is hindered when the text is embossed or debossed without contrast between the
text and the background [13]. Regarding users’ preference, expiration date printed in black
type on a white contrasting background on packages and on blister packs was preferred over
debossing of text without color by 98.6% and 97.6% of participants, respectively.
On blister packs, the readability of information can be affected by the type of material used.
Reflective foils, such as uncoated aluminum foil, reduce the visibility of information, especially
Fig 4. Users’ acceptance of possible label improvements. (n = 6225).
https://doi.org/10.1371/journal.pone.0212173.g004
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when such information is printed in a light color on a low-contrast color background [13]. In
the present study, simulated blister packs with an uncoated aluminum foil surface as the print-
ing surface were strongly rejected by the participants. Ideally, information should be printed
on non-reflective matt foils or colored foils [6, 13].
Information printed on blister packs is essential for the correct identification of the medica-
tion by the user, especially when the outer package and accompanying package inserts are dis-
carded. In this respect, information printed on blister packs must remain available until the
last unit dose is removed [6, 12, 13]. Therefore, the information should be repeated on each
blister pocket in order to improve the readability of key information and allow the correct
identification of the medication [6, 12, 13]. The importance of this recommendation was rec-
ognized by the interviewed users, since 95.6% of them preferred the information repeated on
each blister pocket over the information printed across the entire blister strip, where the text
can be damaged when the medication is removed.
According to users’ opinions, indications for use and contraindications should also appear
on the label. More than 90% of participants found it important that information on what the
medication is used for and who cannot take the medication be displayed on the label. From
the users’ point of view, some studies indicate that, in addition to information that helps iden-
tify the medication, the indications, dose, dosage, and associated risks are viewed as the most
Table 3. Medication users’ labeling preferences obtained through the evaluation of simulated packages. (n = 6,225a).
Secondary package–Drug cartons Primary package–Blister packs
Labeling aspects Preference (%) Labeling aspects Preference (%)
Minimum font size for drug name Background color
Arial 7.5 point 20.0 Aluminum foil 1.1
Arial 11 point 13.9 White 98.1
Arial 14 point 18.1 Indifferent 0.8
Arial 16 point 48.0 Information on each blister pocket
Difference between doses Yes 95.6
Not highlighted 7.9 No 2.1
Highlighted 83.2 Indifferent 2.3
Indifferent 8.9 Expiration date
Orientation of text Engraving (embossing or debossing) 1.9
Vertical 63.0 Black print 97.6
Horizontal 25.7 Indifferent 0.5
Indifferent 11.3 Prototypesa
Background color Standard 18.1
Blue 37.9 Proposed 77.0
White 52.4 Indifferent 4.9
Indifferent 9.7 Prototypes with dose highlighted a
Expiration date Standard 16.2
Engraving (embossing or debossing) 0.3 Proposed 80.1
Black print 98.6 Indifferent 3.7
Indifferent 1.1




a The 2 final simulations were evaluated by the total sample of respondents, while each individual aspect of interest was evaluated by ¼ of the sample.
https://doi.org/10.1371/journal.pone.0212173.t003
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important information [28–31]. The importance of such information for most respondents
may suggest that users are interested in obtaining information because they perceive a need to
deal with issues related to their health. In Brazil, the description of therapeutic indications on
the label is mandatory only for over-the-counter medications.
Based on the results of the present study, there is a clear need for improvement in medica-
tion labels. Most improvements proposed to users were widely accepted when tested individu-
ally. The final simulated packages, which combined the individually tested improvements,
were preferred by 77% (Fig 3A) and 80.9% (Fig 3B) of participants, confirming the low level of
satisfaction of users with current labels and a preference for change. In the final simulations,
there was a clear preference of users for factors that improved readability, such as increased
font size, use of graphic elements and color to highlight the concentration of the active ingredi-
ent, and contrast between the font color and background.
We carried out bivariate analyses to check for possible associations between the variables
gender, age, and schooling and the two final simulated packages presented to respondents (Fig
3). We found that the horizontal prototypes were preferred by women, by younger respon-
dents, and by those with higher levels of education, although the difference was modest (data
not shown). On the other hand, the elderly and the interviwees with lower levels of education
preferred the vertical prototypes. It is possible that older respondents and those with less lower
level of schooling preferred vertical labels due to greater cognitive difficulty in these groups,
and that, regardless of the type of label or packaging, these individuals would experience diffi-
culties in reading and comprehension. Particularly for people with a lower level of schooling
or health literacy, medication labels (and package inserts) should be a complement, not a sub-
stitute for verbal information provided by health professionals.
Only a few studies have focused on surveying users’ opinions and, mainly, their understanding
of medication labels, especially in developing countries. To our knowledge, this is the largest study
evaluating users’ understanding, perception, cognition and preferences regarding medication
labels, with over 6,000 people interviewed, in a complex sampling process, with cluster sampling
and systematic selection of participants. This study characterized users’ perceptions of the readabil-
ity and comprehensibility of medication labels available in Brazil by interviewing a comprehensive
sample of medication users living in capital cities of the 5 macro regions of Brazil. As stated earlier,
medication labels tend to show similarities across different countries. Therefore, our findings may
be considered generalizable to different contexts, especially to low- and middle-income countries,
where the educational and sociocultural level of the population may be closer to that of Brazil than
of high-income countries. Of note, Brazil is a continental country with high population variability
across different regions, which has a positive impact on the external validity of our findings.
Our study included only state capital cities, with a population ranging from 332 thousand
to 12 million inhabitants, which may be considered a limitation of the study. Although the use
of simulated packages to evaluate users’ preferences is a differential advantage of this study
over other studies on this topic, the simulated packages were presented as 2D images under
standard conditions. Therefore, we cannot state that, if physical package prototypes were used,
which allow greater interaction between the user and the package, users’ perceptions of the
readability and comprehensibility of information would remain the same.
Users’ difficulties in reading and understanding medication labels were evident from the
findings of the present study. These difficulties reflect the need for improvements in labels in
order to make them clearer and self-explanatory to users. The proper identification of infor-
mation presented on the label is important for safe medication use, since studies have shown
that a portion of medication errors is due to labeling confusion [1, 7]. In this respect, we con-
cluded that increased font size, use of graphic elements, color and contrast, and use of coherent
hierarchical levels of information in the design of packages to emphasize critical information,
Medication users’ labeling preferences
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such as concentration and expiration date, are factors that contribute to making medication
labels clearer to users. Pharmaceutical industries and policy makers should consider these
items when developing labels and defining policies on this issue.
We also identified the importance of involving users, particularly those with greater diffi-
culty in understanding labels (older, less educated, and non-white individuals), in the develop-
ment of policies and regulatory strategies aimed at medication labeling. Users’ perceptions,
preferences and opinions can contribute to the design of safer labels for the population, mini-
mizing medication errors and, consequently, having a positive impact on public health. The
strategy of incorporating users’ perception into the development of regulations is a way of
bringing developers and users closer together. By recognizing users’ needs, public policies can
be shaped within an experimental, evidence-based framework.
In our study, the participants preferred the labels that met international standards, includ-
ing increased font size and use of graphic elements and color to emphasize critical informa-
tion, such as expiration date and concentration. Although there is a national standard in Brazil
that establishes rules for medication labels [16], this standard has several deficiencies, many of
which correspond to the issues identified by the respondents. The findings of this study may
help developing countries, such as Brazil, develop or revise their local regulations so that medi-
cation labels both meet user preferences and are as close as possible to international (e.g.,
European Union, United Kingdom, Canada, Australia) standards. Likewise, it may help drug
companies that produce medications for developing countries where no official standard may
exist. Pharmaceutical industries should apply these principles and involve users in the design
of medication labels, focusing on patient safety rather than merely on business strategies.
In conclusion, based on users’ perceptions, increased font size and use of graphic elements
and color to emphasize critical information–such as expiration date and concentration ¬–are
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